Table 1. Characteristics of the Overall Sample and the Subgroup With Follow-up Data.
| Characteristic | No. (%) | P value | ||
|---|---|---|---|---|
| Total eligible sample (n = 3779) | Sample with known abortion outcome (n = 2397) | Sample without known abortion outcome (n = 1382) | ||
| Age at mifepristone provision, y | ||||
| ≤24 | 1186 (31.4) | 761 (31.7) | 425 (30.8) | .23 |
| 25-34 | 1904 (50.4) | 1206 (50.3) | 698 (50.5) | |
| ≥35 | 689 (18.2) | 430 (17.9) | 259 (18.7) | |
| Race and ethnicity | ||||
| Black | 870 (23.0) | 536 (22.4) | 334 (24.2) | .008 |
| Latinx/Hispanic | 533 (14.1) | 346 (14.4) | 187 (13.5) | |
| White | 1623 (42.9) | 1034 (43.1) | 589 (42.6) | |
| Multiracial or othera | 327 (8.7) | 223 (9.3) | 104 (7.5) | |
| Unknown | 426 (11.3) | 258 (10.8) | 168 (12.2) | |
| Residenceb | ||||
| Urban | 2785 (73.7) | 1702 (71.0) | 1083 (78.4) | .98 |
| Suburban | 243 (6.4) | 153 (6.4) | 90 (6.5) | |
| Rural | 607 (16.1) | 430 (17.9) | 177 (12.8) | |
| Unknown | 144 (3.8) | 112 (4.7) | 32 (2.3) | |
| Payment methodsc | ||||
| Private insurance | 769 (20.3) | 546 (22.8) | 223 (16.1) | <.001 |
| Medicaid | 881 (23.3) | 581 (24.2) | 300 (21.7) | .08 |
| Abortion fund | 212 (5.6) | 140 (5.8) | 72 (5.2) | .95 |
| Patient | 1903 (50.4) | 1111 (46.3) | 792 (57.3) | .10 |
| Site subsidy | 46 (1.2) | 21 (0.9) | 25 (1.8) | .13 |
| Unknown | 274 (7.3) | 217 (9.1) | 57 (4.1) | <.001 |
| Previous medication abortion | ||||
| None | 2626 (69.5) | 1696 (70.8) | 930 (67.3) | .002 |
| Any | 748 (19.8) | 450 (18.8) | 298 (21.6) | |
| Unknown | 405 (10.7) | 251 (10.5) | 154 (11.1) | |
| Participated in the TelAbortion study | ||||
| No | 3354 (88.8) | 2031 (84.7) | 1323 (95.7) | <.001 |
| Yes | 425 (11.2) | 366 (15.3) | 59 (4.3) | |
| Method of mifepristone provision | ||||
| In person | 2511 (66.4) | 1670 (69.7) | 841 (60.9) | <.001 |
| Mailed | 1268 (33.6) | 727 (30.3) | 541 (39.1) | |
| No. of misoprostol tablets initially prescribed | ||||
| 4 × 200 μg | 2034 (53.8) | 1267 (52.9) | 767 (55.5) | <.001 |
| 8 × 200 μg | 1745 (46.2) | 1130 (47.1) | 615 (44.5) | |
| Method of misoprostol provision | ||||
| Dispensed with mifepristone | 3766 (99.7) | 2386 (99.6) | 1380 (99.9) | .85 |
| Prescription | 12 (0.3) | 10 (0.4) | 2 (0.1) | |
| Unknown | 1 (0.0) | 1 (0.0) | 0 (0.0) | |
| Pregnancy duration by last menstrual period at mifepristone provision, dd | ||||
| <43 | 1400 (37.0) | 904 (37.7) | 496 (35.9) | <.001 |
| 43-56 | 1700 (45.0) | 1080 (45.1) | 620 (44.9) | |
| 57-70 | 611 (16.2) | 365 (15.2) | 246 (17.8) | |
| >70 | 62 (1.6) | 43 (1.8) | 19 (1.4) | |
| Unknown | 6 (0.2) | 5 (0.2) | 1 (0.1) | |
a
The “other” category included Alaska Native, American Indian, Asian, Asian Indian, Filipino, Guyanian, Guamanian/Chamorro, Japanese, Middle Eastern, Native American, Native Hawaiian, Pacific Islander, and Turkish.
b
Estimated based on patient zip codes using Rural-Urban Commuting Area codes data.27
c
Multiple payment options may apply.
d
For the mailed group, pregnancy duration was calculated based on the date the medications were mailed.